Rahul Kakkar, Tome Biosciences CEO

Ex­clu­sive: Weeks af­ter $213M launch, Tome ac­quires a Berke­ley gene edit­ing start­up for DNA lig­ase tech­nol­o­gy

Less than a month af­ter launch­ing with $213 mil­lion in fund­ing, gene edit­ing com­pa­ny Tome Bio­sciences has ac­quired a tiny Cal­i­forn­ian start­up called Re­place Ther­a­peu­tics to ex­pand its reper­toire of DNA-al­ter­ing tools. Tome will pay Re­place $65 mil­lion in up­front and near-term mile­stone pay­ments and up to $185 mil­lion to­tal in stock and cash, the com­pa­ny told End­points News.

Tome was found­ed by a pair of MIT sci­en­tists who de­vel­oped a twist on CRISPR gene edit­ing tech­nol­o­gy, in­sert­ing large DNA se­quences that are thou­sands of let­ters long in­to pre­cise lo­ca­tions in the genome. Tome’s new tech­nol­o­gy from Re­place is bet­ter suit­ed for mak­ing small­er changes to the genome on the or­der of tens to hun­dreds of let­ters, the start­up said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.